Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2018

  • ID: 4521337
  • Drug Pipelines
  • 98 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AFFiRiS AG
  • Betagenon AB
  • Biocad
  • Bioleaders Corp
  • BioLingus AG
  • Innovent Biologics Inc
  • MORE
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'Proprotein Convertase SubtilisinKexin Type 9 - Pipeline Review, H1 2018'; Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) pipeline Target constitutes close to 27 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes.

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene. It is a crucial player in the regulation of plasma cholesterol homeostasis.

It binds to low-density lipid receptor family members. It acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. It prevents the recycling of LDLR from endosomes to the cell surface or directs it to lysosomes for degradation. It induces ubiquitination of LDLR leading to its subsequent degradation. It inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner.

The report 'Proprotein Convertase SubtilisinKexin Type 9 - Pipeline Review, H1 2018' outlays comprehensive information on the Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 4, 3, 10, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Cardiovascular, Gastrointestinal and Oncology which include indications Hypercholesterolemia, Hyperlipidemia, Atherosclerosis, Cardiovascular Disease, Homozygous Familial Hypercholesterolemia (HoFH), Type 2 Diabetes, Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), Liver Diseases, Metabolic Syndrome, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH) and Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.)
  • The report reviews Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AFFiRiS AG
  • Betagenon AB
  • Biocad
  • Bioleaders Corp
  • BioLingus AG
  • Innovent Biologics Inc
  • MORE
Introduction

Report Coverage

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Overview

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Companies Involved in Therapeutics Development

AFFiRiS AG

Betagenon AB

Biocad

Bioleaders Corp

BioLingus AG

Dicerna Pharmaceuticals Inc

Ensemble Therapeutics Corp

Innovent Biologics Inc

Kowa Co Ltd

Noxopharm Ltd

Pfizer Inc

Portola Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

The Medicines Company

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Drug Profiles

AK-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alirocumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-04A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-06A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLSM-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CiVi-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVILM-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCRPCSK-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBI-306 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inclisiran - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JS-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-312 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit PCSK9 for Cardiovascular Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NYX-330 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

O-304 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06446846 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PCSK9 for Cardiovascular Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PCSK9 for Hyperlipidemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SX-PCK9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UBP-1214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Dormant Products

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Discontinued Products

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Product Development Milestones

Featured News & Press Releases

Mar 10, 2018: Praluent (alirocumab) Significantly Reduced Risk of Cardiovascular Events in High-risk Patients, and was Associated with Lower Death Rate

Mar 10, 2018: Regeneron and Sanofi Announce Plans to Make Praluent (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need

Mar 08, 2018: The Medicines Company Reaches Enrollment Target for ORION-10 Ahead of Schedule

Feb 20, 2018: The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule

Jan 25, 2018: Inclisiran’s First Pivotal Trial Achieves Target Enrollment Ahead of Schedule

Nov 07, 2017: Regeneron and Sanofi to Present New Analyses from the Praluent (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2

Nov 06, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran

Nov 02, 2017: Betagenon/Baltic Bio Announces Positive Results From a 28-day Phase IIa Trial of the First-in-class AMPK Activator O304 in Type 2 Diabetics

Oct 05, 2017: Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent (alirocumab)

Aug 28, 2017: New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials

Aug 25, 2017: Regeneron and Sanofi to Present New Analyses from Praluent Injection Trials at the ESC Congress 2

Jun 11, 2017: Medication That Inhibits PCSK9 Safely Reduces Cardiovascular Risk in Patients with Type 2 Diabetes

Jun 11, 2017: Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia

Apr 26, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran

Apr 25, 2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by AFFiRiS AG, H1 2018

Pipeline by Betagenon AB, H1 2018

Pipeline by Biocad, H1 2018

Pipeline by Bioleaders Corp, H1 2018

Pipeline by BioLingus AG, H1 2018

Pipeline by Dicerna Pharmaceuticals Inc, H1 2018

Pipeline by Ensemble Therapeutics Corp, H1 2018

Pipeline by Innovent Biologics Inc, H1 2018

Pipeline by Kowa Co Ltd, H1 2018

Pipeline by Noxopharm Ltd, H1 2018

Pipeline by Pfizer Inc, H1 2018

Pipeline by Portola Pharmaceuticals Inc, H1 2018

Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018

Pipeline by The Medicines Company, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AFFiRiS AG
  • Betagenon AB
  • Biocad
  • Bioleaders Corp
  • BioLingus AG
  • Dicerna Pharmaceuticals Inc
  • Ensemble Therapeutics Corp
  • Innovent Biologics Inc
  • Kowa Co Ltd
  • Noxopharm Ltd
  • Pfizer Inc
  • Portola Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • The Medicines Company
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll